A recent European study20 demonstrated an association of P/LP germline CDH1 truncating alterations with LBCs, not fulfilling the 2020 HDGC criteria.7 However, the exact LBC risk in this nonclassic context is under evaluation; it seems variable in accordance with some different clinical phenotypes.31,32,33 Our study demonstrated a significantly earlier age at diagnosis of LBC manifestation in P/LP CDH1 variant carriers compared with other groups (wild-type, VUS plus B/LB) and also BRCA1 and BRCA2 genes. Here, BRCA2 is linked to CDH1-related diffuse gastric and lobular breast cancer syndrome.